| AAO urges physician, public awareness
| The American Academy of Ophthalmology (AAO), which said it was "pleased with the timely JAMA article," is reminding physicians to emphasize the importance of good hygiene practices to their patients who wear contact lenses. | | | CDC study confirms Fusarium link to contact lens solution
|
| A new study confirms preliminary findings that a unique outbreak of Fusarium keratitis this past spring was associated with use of ReNu with MoistureLoc (Bausch & Lomb) contact lens cleaning solution and common suboptimal hygiene practices (JAMA 2006;296:953-963). | |  MORE ARTICLES
|
|  |
| Cataract common complication of IVTA for DME
| | Las Vegas—When considering the use of intravitreal triamcinolone acetonide (IVTA) in patients with diabetic macular edema (DME), ophthalmologists should be mindful that cataract is a common complication and is particularly challenging in young patients with clear lenses and still-useful accommodation, according to a study reported by Moncef Khairallah, MD, here at the annual meeting of the American Academy of Ophthalmology. | | | MORE ARTICLES
|
| |
| Drs. Kaufman, Watson named journal editors-in-chief
| | Rockville, MD—The Association for Research in Vision and Ophthalmology (ARVO) selected Paul L. Kaufman, MD, as editor-in-chief of Investigative Ophthalmology & Visual Science, and Andrew B. Watson, PhD, as editor-in-chief of Journal of Vision. | | | Tolle leads WaveLight's U.S. operations as CEO
| | Sterling, VA—Wolfgang Tolle has been appointed as the new chief executive officer (CEO) of U.S. operations for WaveLight Inc., a subsidiary of WaveLight AG. In his new post, Tolle will assume responsibility for all business activities at the U.S. based-subsidiary and will report to WaveLight AG's CEO Max Reindl. | | | Dr. Boorady appointed COO of Eyemaginations
| | Towson, MD—Eyemaginations Inc. announced the appointment of Joseph Boorady, OD, as chief operating officer. Dr. Boorady joins Eyemaginations from his previous position as vice president for clinical affairs and executive director of the University Optometric Center at the SUNY College of Optometry, New York. | | | Niksch selected as industry representative on FDA panel
| | Irvine, CA—Barbara A. Niksch, MBA, has accepted an appointment from the U.S. Department of Health and Human Services to serve as industry representative on the FDA's Ophthalmic Devices Panel of the Medical Devices Advisory Committee. Niksch is vice president of regulatory, quality, and clinical affairs, Visiogen Inc. | | | Dr. Wafapoor joins staff at Retina Health Center
| | Fort Myers, FL—Retina Health Center is pleased to announce the addition of Hussein Wafapoor, MD, to the staff of its Fort Myers and Naples, FL, offices. Dr. Wafapoor brings extensive experience in the treatment of retinal disorders, particularly diabetic retinopathy and age-related macular degeneration. | | | B&L's O'Brien named VP of global refractive strategy
| | Rochester, NY—Bausch & Lomb has named Dennis O'Brien to the position of vice president, global refractive strategy. O'Brien was most recently a member of the company's Americas commercial leadership team, based in Toronto as general manager of Bausch & Lomb Canada. An engineer by training, O'Brien joined Bausch & Lomb in 1992, and progressed through a variety of manufacturing leadership positions before becoming vice president, global supply chain operations for the Americas contact lens business. | | | Dr. Campbell joins Sophrona advisory board
| | Minneapolis—Robert C. Campbell, MD, has joined the advisory board of Sophrona Solutions. | | | Dr. Khurana receives AMA Foundation award
| | Washington, DC—Rahul N. Khurana, MD, from Santa Monica, CA, has been named a recipient of the American Medical Association (AMA) Foundation's 2007 Leadership Award. This award provides medical students, residents/fellows, young physicians, and international medical graduate physicians from around the country with special training to develop their skills as future leaders in organized medicine. | | | Dr. Whitman elected president of ACES
| | Dallas—The American College of Eye Surgeons (ACES) has named Jeffrey Whitman, MD, president of the national organization for a 2-year term. Dr. Whitman is medical director and chief surgeon of Dallas-based Key-Whitman Eye Center and has been practicing ophthalmic surgery for more than 20 years. | | | MORE ARTICLES
|
| |
| Alexander joins Vistakon as director, professional affairs
| | Jacksonville, FL—Carol Alexander, OD, FAAO, has joined Vistakon Inc. as director, professional affairs. Dr. Alexander is a private practitioner, with more than 20 years in practice. She is a past president of the Ohio Optometric Association (OOA) and has also served on several national American Optometric Association (AOA) committees in the areas of regulation and legislation. | | | Zeiss Vision promotes Howard, Packham
| | Petaluma, CA—Carl Zeiss Vision has announced that Frederick Howard has been named president and general manager, Americas. He replaces Barry Packham, PhD, who has moved into the newly created role of executive vice president, global operations. | | | Robert Marc names KEM as agency of record
| | New York—Eyewear designer Robert Marc has appointed Ketchum Entertainment Marketing (KEM) as public relations agency for his collection of custom-made sun and eyewear. As part of its ongoing media relations and marketing campaigns, KEM will work to expand the brand's positioning with fashion and celebrity influences, consumer publications, and leverage product placement in film and television. | | | MORE ARTICLES
|
| |
| Wilmer Eye Institute breaks ground on new, upgraded facility
| | The Wilmer Eye Institute of Johns Hopkins University School of Med-icine opened a $100 million, privately funded, 207,000-square-foot facility that will build on the current research and clinical space for its 130 full-time faculty (90 clinician scientists; 40 PhD researchers). | | | AMO recalls lens solution
| | In response to reports received from the Centers for Disease Control and Prevention (CDC) regarding eye infections from Acanthamoeba, Advanced Medical Optics (AMO) has voluntarily recalled its Complete MoisturePlus contact lens solutions. No evidence suggests that the voluntary recall is related to a product contamination issue, according to AMO. The company is working with the CDC, FDA, and others to ensure that consumers are aware of the need for proper contact lens disinfection and proper lens handling. | | | Trials begin on drop to heal ocular wounds
| | Bethesda, MD?The FDA will allow Regene-Rx Biopharmaceuticals Inc. to begin a phase II trial of its Thymosin beta 4 (TB4) for the treatment of diabetic patients undergoing vitrectomy surgery. | | | Trials to test efficacy of ocular implants
| | Lincoln, RI?Biotechnology firm Neurotech Pharmaceuticals Inc. has begun two phase II/III clinical trials with NT-501, the company's lead Encapsulated Cell Technology (ECT) product for the treatment of visual loss associated with retinitis pigmentosa. | | | The price of vision
| | Chicago?The aggregate cost related to adult vision conditions in the United States has climbed to an estimated $51.4 billion, according to a pioneering report from Prevent Blindness America (PBA). | |
| | Photochromic IOL to be available in Europe
| | Irvine, CA?Medennium Inc. expects that its photochromic IOL (Aurium) will be available in all European countries by September now that it has obtained CE mark clearance to market the lens. It is the first and only photochromic IOL, according to the company. | | | Spreading agent introduced to market
| | San Diego?Baxter Healthcare Corp. has launched its hyaluronidase human injection (Hylenex recombinant) for use in enhancing the absorption and dispersion of injected ophthalmic anesthetics. | | | AMO phaco system offers dual-pump fluidics
| | San Diego?Advanced Medical Optics (AMO) Inc. has introduced a new phacoemulsification system featuring dual-pump fluidics (WhiteStar Signature with Fusion). | | | Cyclosporine A tested for dry eye
| | Tampa, FL?Two companies are researching cyclosporine A as a potential treatment for dry eye syndrome. | | | MORE ARTICLES
|
| |
| Multiple factors guide decisions for post-SLT management
| | San Francisco—Selective laser trabeculoplasty (SLT) is a major advance in the management of glaucoma because it safely and effectively lowers IOP without damaging or disrupting the trabecular beams. | | | SLT appears effective for steroid-induced glaucoma
| | New York—The idea of using selective laser trabeculoplasty (SLT) for steroid-induced glaucoma originated with a patient's stubborn resistance to surgery, according to Janet P. Serle, MD. | | | SLT comparable with medical therapy for open-angle glaucoma
| | Las Vegas—Selective laser trabeculoplasty (SLT) is comparable to medical treatment as the initial therapy for open-angle glaucoma (OAG) or ocular hypertension, according to results of a study reported by L. Jay Katz, MD, and colleagues here at the American Academy of Ophthalmology annual meeting. | | | SLT may be useful as primary glaucoma therapy
| | London, Ontario—During at least the first 12 months after treatment initiation, selective laser trabeculoplasty (SLT) and latanoprost 0.005% (Xalatan, Pfizer) are associated with equivalent efficacy and safety profiles when used as primary therapy for newly diagnosed open-angle glaucoma or ocular hypertension, according to the results of a prospective, multicenter, parallel comparison, clinical trial conducted by researchers at Ivey Eye Institute, University of Western Ontario, London. | | | MORE ARTICLES
|
|
|
| 
